AuraSense Therapeutics (Evanston, IL) a development-stage biotechnology company focused on nucleic acid constructs for heart disease, cancer, skin conditions and bacterial infection, closed a $4.5M Series B financing. Participants include Abbott Biotech Ventures.

SARcode (Brisbane, CA) a clinical-stage biopharmaceutical company focused on chronic T-cell mediated inflammation in ophthalmic and dermatologic disease, closed a $44M Series B financing. Participants include Sofinnova Ventures, Rho Ventures, Alta Partners and Clarus Venture Partners.
Thanx for your patience as we catch-up.

Kythera Biopharmaceuticals (Calabasas, CA) a clinical-stage biopharmaceutical company focused on aesthetic dermatology, closed a $37.4M Series D financing. Participants include Versant Ventures, Arch Venture Partners, Prospect Venture Partners, Jafco Ventures, Invus Financial Advisors, BBT Capital Management, Altitude Life Science Ventures and Foley Ventures.

Revance Therapeutics (Newark, CA) a clinical-stage biopharmaceutical company developing botulinum toxin type A products focused on topical indications such as lateral canthal lines and hyperhidrosis, closed a $45M Series E financing. Participants include Essex Woodlands Health Ventures, NovaQuest Capital, CNF Investments, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Pac-Link Ventures and Essex Capital [...]

Lotus Tissue Repair (Cambridge, MA) a development-stage biopharmaceutical company focused on dystrophic epidermolysis bullosa and other dermatologic conditions, closed a $26M Series A financing. Participants include Third Rock Ventures.

Delenex (Switzerland) a preclinical-stage biopharmaceutical company focused on CNS and dermatological diseases closed a $19.3M Series A financing, bringing the total round to $38.4M. Participants include Novo Ventures, SV Life Sciences, HBM BioCapital, HBM BioVentures, BioMedInvest and VI Partners.

Arbor Pharmaceuticals (Atlanta, GA) a commercial-stage specialty pharmaceutical company atopic dermatitis and otic conditions, closed a $17.5M Series B financing. Participants include Signet Healthcare Partners.

Delenex Therapeutics (Switzerland) a clinical-stage biopharmacetucial company developing therapeutic antibody fragments targeting CNS and dermatological disease, closed a $14M Series A financing. Participants include SV Life Sciences, HBM BioCapital, BioMed Partners and VI Partners.

ReVance Therapeutics (Mountain View, CA) a clinical-stage biopharmaceutical company focused on dermatology and aesthetic medicine, closed a $25.6M Series D financing. Particpants have included Essex Woodlands Health Ventures, Vivo Ventures, Technology Partners, Shepherd Ventures, Palo Alto Investors, Bio*One Capital and Pac-Link Venture.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Quinnova Pharmaceuticals (Newtown, PA) a commercial-stage specialty biopharma company focused on dermatological drug reformulations and foam delivery systems, closed a $17.4M Series B financing. Participants include Safeguard Scientifics, Thomas, McNerney & Partners, H.I.G. Ventures.

ProCertus BioPharm (Madison, WI) a clinical-stage developer of treatments to combat the side effects of chemotherapy and radiotherapy, e.g. alopecia, dermatitis and oral mucositis, closed a $2.1M Series A. Participants include Novartis Venture Fund and Venture Investors.

Kythera Biopharmaceuticals (Calabasas, CA) a clinical-stage biopharmaceutical company focused on aesthetic dermatology, closed a $10M Sereis C financing, bringing the total round to $40M. Participants include Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, BBT Capital Management, JAFCO Ventures and Altitude Life Science Ventures.

Garnet Biotherapeutics (Malvern, PA) a regenerative medicine company focused on dermatology, closed a $10.4M Series A financing. Participants include SCP Vitalife Partners, Safeguard Scientifics and Alliance Technology Ventures.